Status:
COMPLETED
Insulin Titration System Based on Deep Learning
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Diabetes Mellitus Type 2 - Insulin-Treated
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This is an open-labeled, one-arm intervention trial to access the effect and safety of the Insulin Titration System Based on Deep Learning in patients with Type 2 Diabetes Mellitus.
Detailed Description
The study enrolls 13 patients with Type 2 Diabetes in Zhongshan Hospital who are on treatment with insulin. After screening for the inclusion and exclusion criteria, eligible patients will receive ins...
Eligibility Criteria
Inclusion
- type 2 diabetes
- age of 18-75 years
- HbA1c between 7.0% and 11.0%.
Exclusion
- subjects with acute complications of diabetes, such as ketoacidosis or hyperglycemic hyperosmolar state;
- BMI ≥ 45kg/m2;
- women who are pregnant or breast-feeding;
- subjects with severe cardiac, hepatic, renal diseases; subjects with any psychiatric or psychological diseases;
- subjects with severe edema, infections or peripheral circulation disorders, receiving surgery during hospitalization;
- subjects who could not comply with the protocol
Key Trial Info
Start Date :
June 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 6 2022
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT05409391
Start Date
June 15 2022
End Date
October 6 2022
Last Update
June 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Endocrinology, Zhongshan Hospital Fudan University
Shanghai, China